Clinical trials: Human Immunodeficiency Virus I Infection
HIV I Infection, Injection Pain
Impact of Pain From Injectables Antiretroviral Treatments in HIV-1 Patients Based on the Injection Site (Ventrogluteal or Dorsogluteal) and the Use or Non-use of Virtual Reality Headset
This is a multicenter, randomized, open-label study with a cross-over design. The objective of this project is to compare the intensity of pain induced by injectable antiretroviral (ARV) treatment (Cabotegravir® and Rilpivirine®)…
- Trial name
- VIHINJECT (NCT06834113)
- Testing
- Dorsogluteal intramuscular injection
- Where
- 5 sites in France
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Infection, Human Immunodeficiency Virus I, HIV Infection
GW873140 In Combination With Kaletra In HIV Infected Subjects
This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Kaletra in HIV infected, untreated subjects.
- Trial name
- NCT00102778
- Testing
- GW873140, Kaletra (lopinavir/ritonavir)
- Where
- 70 sites in United States, Canada and 8 more
- Volunteers
- 175 people
- Sponsor
- ViiV Healthcare
HTLV-I Infection
Raltegravir for HAM/TSP
Background: Human T-cell lymphotropic virus type 1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) is an infection of the spinal cord.
- Trial name
- NCT01867320
- Testing
- Raltegravir
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Healthy Subjects, Infection, Human Immunodeficiency Virus
GSK1349572 Drug Interaction Study With Protease Inhibitors
A study in healthy volunteers to determine whether there is a drug interaction between GSK1349572 and the HIV protease inhibitors lopinavir/ritonavir and darunavir/ritonavir
- Trial name
- NCT00774735
- Testing
- GSK1349572
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Immunodeficiency Virus
Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults
This is a Phase I, randomized, double-blind, placebo-controlled clinical study to define the safety and immunogenicity resulting from a rapid dose-escalating vaccination schedule as compared to that of a co-administered…
- Trial name
- RV591 (NCT06205056)
- Testing
- Ad26.Mos4.HIV in CH505 TF chTrimer + ALFQ [Arm 1a], CH505 TF chTrimer + ALFQ [Arm 1a], Ad26.Mos4.HIV in CH505 TF chTrimer +ALFQ [Arm 2a]
- Where
- Uganda
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
HIV Infections
A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes
AMENDED: To investigate whether subcutaneous (SC) injection of IL-2 produces biological responses which parallel those observed with IV dosing.
- Trial name
- NCT00001005
- Testing
- Zidovudine, Aldesleukin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome, HIV Infection
Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative Volunteers
This is a randomized, double blind study of the safety and immunogenicity of APL 400-003, a plasmid DNA vaccine encoding the env and rev genes of HIV-1, in HIV-negative volunteers.
- Trial name
- NCT00001538
- Testing
- APL 400-003
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Cytopenias
An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia
To determine the safety, immunogenicity, biological activity, ad pharmacokinetics of sargramostim ( recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF ) human granulocyte-macrophage colony-stimulating factor …
- Trial name
- NCT00002008
- Testing
- Sargramostim
- Where
- 2 sites in United States
- Sponsor
- Sandoz
HIV Infections
Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection
At the end of 2004 there were more than 40 million people infected worldwide with HIV, with an estimated 16,000 new infections every day (Joint United Nations Programme on HIV/AIDS [UNAIDS], 2004).
- Trial name
- NCT00386633
- Testing
- MVA-mBN32
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Infection, Human Immunodeficiency Virus I
A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
This is a single-center, open-label, three-period, fixed-sequence cross over study in healthy adult subjects. A total of approximately 16 healthy subjects will be enrolled to provide data from 12 evaluable subjects.
- Trial name
- NCT01283100
- Testing
- GSK1349572, GSK2248761
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus I Infection
Optimization of Darunavir Therapy and Dosage Recommendations
This study will assess and characterize the variability observed in the response to darunavir therapy, an antiretroviral medication used against the Human Immunodeficiency Virus (HIV).
- Trial name
- NCT03101644
- Testing
- Darunavir
- Where
- Belgium
- Volunteers
- 127 people
- Sponsor
- Université Catholique de Louvain
HIV Infections
Phase I Pharmacokinetic and Tolerance Study of Ribavirin in Human Immunodeficiency Virus (HIV) - Infected Patients
To determine how fast ribavirin reaches the bloodstream, what concentration of ribavirin is reached in blood and how long it remains in the blood (pharmacokinetics) when given by different routes of administration.
- Trial name
- NCT00000733
- Testing
- Ribavirin
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus, Hepatitis B
Notification of Donors With Positive Microbiology Markers
Each year around 200 blood donors in the UK are found to be infected with blood-borne diseases (HIV, hepatitis B, hepatitis C, and HTLV), while several others have been identified as having an increased risk of variant…
- Conditions
- Human Immunodeficiency Virus, Hepatitis B, Hepatitis C, Human T-lymphotropic Virus I & II
- Trial name
- NCT01050881
- Where
- United Kingdom
- Volunteers
- 217 people
- Sponsor
- NHS Blood and Transplant
HIV Infections
HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals
This is a phase I, multi-site, study of the safety, immunologic and virologic responses of ex vivo expanded HIV-1 multi-antigen specific T-cell therapy (HST-NEET) as a therapeutic strategy in HIV-infected individuals suppressed…
- Trial name
- RESIST (NCT03485963)
- Testing
- HST-NEETs
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Catherine Bollard
HIV Infection
Study of Single IV Administration of P2G12
A randomised phase I trial of a monoclonal antibody which neutralises HIV-1 (P2G12) to be given as a single intravenous infusion to healthy human volunteers to assess the safety and reactogenicity
- Trial name
- FuturePharma (NCT02923999)
- Testing
- P2G12 Dose Cohort 1, P2G12 Dose Cohort 2, P2G12 Dose Cohort 3
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
Latent Tuberculosis Bacteriology and Histology Unknown, Latent Tuberculosis
A Phase I/IIa AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection (C-035-456)
This is a Phase I/IIa, double-blind, randomized, placebo-controlled, dose- and regimen-finding study in healthy adults with and without LTBI, who are BCG-vaccinated, HIV negative, and have no history or evidence of TB disease.
- Trial name
- NCT01865487
- Testing
- H56ug/IC31nmol
- Where
- 2 sites in South Africa
- Volunteers
- 98 people
- Sponsor
- Aeras
HIV Infection
A Safety and Immunogenicity Trial of IHV01
This study is designed to evaluate the safety of the FLSC vaccine and will be a randomized, placebo-controlled, modified double-blinded dose escalation study in 60 healthy adult volunteers (Human Immunodeficiency Virus-1…
- Trial name
- FLSC-001 (NCT02756208)
- Testing
- 300 ug FLSC vaccine, 150 ug FLSC vaccine, 75 ug FLSC vaccine
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
HTLV-I Infections, HTLV-II Infections
MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study
This post-market study is intended to assess the performance of the HTLV Blot 2.4 in repository serum/plasma specimens with neurological disorders (n=100) or an HTLV known positive infection (n=50).
- Conditions
- HTLV-I Infections, HTLV-II Infections, Human T-lymphotropic Virus 1, Human T-lymphotropic Virus 2
- Trial name
- NCT03226119
- Testing
- MP Diagnostics HTLV Blot 2.4
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- MP Biomedicals, LLC
HIV Infection
Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers
The development of a safe and effective HIV-1 vaccine strategy would probably be the best solution for the ultimate control of the worldwide AIDS pandemic.
- Trial name
- VRI01 (NCT02038842)
- Testing
- LIPO-5, MVA HIV-B (MVATG17401), GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots
- Where
- France
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
A Phase I Pharmacokinetics and Safety Study of Two Dapivirine Intravaginal Gels
IPM 012 is a double-blind, randomized, placebo-controlled phase I study conducted at one research center in Belgium among 36 healthy, HIV-negative women of 18-40 years of age, randomized in a 1:1:1 ratio to assess plasma, vaginal…
- Trial name
- NCT00613249
- Testing
- Dapivirine Gel 4750, 0.05%, 2.5g, Dapivirine Gel 4789, 0.05%, 2.5g
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.